|
Market Closed -
Bombay S.E.
06:02:33 2026-10-26 EDT
|
5-day change | 1st Jan Change | ||
| 4,570.00 INR | +1.96% |
|
+0.43% | +18.96% |
| Market Cap | 1,738B 18.27B 16.34B 15.12B 13.69B 25.61B 26.03B 182B 71.95B 909B 68.57B 67.11B 2,879B | P/E 2027 * |
70.2x | P/E 2028 * | 50.8x |
|---|---|---|---|---|---|
| Enterprise Value | 1,862B 19.57B 17.5B 16.19B 14.66B 27.43B 27.88B 195B 77.06B 974B 73.44B 71.87B 3,083B | EV / Sales 2027 * |
9.33x | EV / Sales 2028 * | 8.17x |
| Free-Float |
41.38% | Yield 2027 * |
0.65% | Yield 2028 * | 0.79% |
| Markets | Quality | ||
|---|---|---|---|
Bombay S.E.
| TORNTPHARM | Delayed | |
NSE India S.E.
| TORNTPHARM | Delayed |
Last Transcript: Torrent Pharmaceuticals Limited
| 1 day | +1.96% | ||
| 1 week | +0.43% | ||
| Current month | -4.82% | ||
| 1 month | -8.32% | ||
| 3 months | -7.86% | ||
| 6 months | +11.04% | ||
| Current year | +18.96% |
| 1 week | 4,465.35 |  | 4,651.4 |
| 1 month | 4,465.35 | | 4,990 |
| Current year | 3,724.1 | | 5,249.95 |
| 1 year | 3,532.85 | | 5,249.95 |
| 3 years | 1,912.5 | | 5,249.95 |
| 5 years | 1,242.5 | | 5,249.95 |
| 10 years | 571.75 | | 5,249.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aman Samir Mehta
CEO | Chief Executive Officer | 34 | 2025-07-31 |
Sudhir Menon
DFI | Director of Finance/CFO | - | 2018-08-31 |
Geena Malhotra
CTO | Chief Tech/Sci/R&D Officer | - | 2026-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 62 | 2014-07-29 | |
Nayantara Bali
BRD | Director/Board Member | 59 | 2019-03-06 |
| Director/Board Member | 59 | 2022-07-28 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 11/29/24 | Buy | Chief Operating Officer | 930,144 | 0.2748% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.96% | +0.43% | +27.71% | +141.64% | 17.96B | |
| +0.45% | +3.13% | +54.96% | +125.16% | 1,135B | |
| +0.94% | +4.93% | +39.86% | +78.72% | 635B | |
| +0.39% | +1.44% | +25.77% | +97.48% | 505B | |
| +1.43% | +4.31% | +46.20% | +67.12% | 378B | |
| -3.21% | -2.10% | +60.72% | +33.22% | 358B | |
| -0.41% | +2.64% | +22.48% | +49.82% | 295B | |
| +0.23% | +3.66% | +2.57% | +23.69% | 266B | |
| +1.22% | +4.63% | +52.40% | +64.85% | 237B | |
| +1.70% | +3.67% | +31.21% | +102.15% | 193B | |
| Average | +0.44% | +2.34% | +36.39% | +78.39% | 402.16B | |
| Weighted average by Cap. | +0.43% | +2.83% | +41.34% | +83.87% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 199B 2.1B 1.87B 1.73B 1.57B 2.94B 2.99B 20.87B 8.26B 104B 7.87B 7.7B 330B | 224B 2.36B 2.11B 1.95B 1.77B 3.3B 3.36B 23.47B 9.28B 117B 8.85B 8.66B 371B |
| Net income | 23.96B 252M 225M 208M 189M 353M 359M 2.51B 992M 12.53B 945M 925M 39.69B | 33.89B 356M 319M 295M 267M 499M 508M 3.55B 1.4B 17.73B 1.34B 1.31B 56.13B |
| Net Debt | 123B 1.3B 1.16B 1.07B 972M 1.82B 1.85B 12.92B 5.11B 64.56B 4.87B 4.77B 204B | 92.93B 977M 873M 808M 732M 1.37B 1.39B 9.72B 3.85B 48.61B 3.67B 3.59B 154B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-26 | ₹4,570.00 | +1.96% | 175,439 |
| 26-10-23 | ₹4,482.00 | -2.78% | 4,442 |
| 26-10-22 | ₹4,610.15 | +1.82% | 3,828 |
| 26-10-21 | ₹4,527.55 | -0.50% | 4,823 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TORNTPHARM Stock
Select your edition
All financial news and data tailored to specific country editions
